Stem Cell Reconstructive Market Research Report - Forecast to 2030

Stem Cell Reconstructive Market Research Report: By Sources (Allogeneic, Autologous, Syngeneic And Other), Cell Types (Embryonic Stem Cell, Adult Stem Cell), Application (Cancer, Diabetes, Traumatic Skin Defect, Severe Burn), End Users (Hospital, Research Institutes) - Forecast Till 2030

ID: MRFR/LS/0487-HCR | November 2022 | Region: Global | 110 Pages         

Stem Cell Reconstructive Market Speak to Analyst Request a Free Sample

Stem Cell Reconstructive Market overview


The Stem cell reconstructive market is expected to reach USD 4,673.3 Million by 2030 at 20.6% CAGR during the forecast period 2022-2030. Stem cell surgery is for to treat the damaged part of the body. Stem cells are generally undifferentiated biological cells. These cells divide to generate more stem cells.  An increasing geriatric population and rising number of patients suffering from various diseases, and the Advancement of technology are boosting the stem-cell reconstructive and plastic surgery demand and growing reconstructive surgeries among patients due to rising number of limbs elimination, implants, and accident boosting the Stem cell reconstructive market growth.

Apart from that, stem cell reconstructive breast surgery is a very common treatment used in case of certain problems. The demand for Stem cell reconstructive surgery market is increasing every day with an increasing number of the aged population.


Stem cell reconstructive is a treatment procedure that uses the patient’s own adipose tissue to increase the fat volume in a particular area of a body. The Stem cell reconstructive is also help in the 3Dimentional reconstruction process in the patients who have gone through trauma or in the past surgical phase such as lumpectomy, reconstructive surgery, brain surgery as a result of an accident. Stem cell reconstructive treatment is also a part of plastic surgeries as well. Stem cell reconstructive can give many benefits to patients going through a variety of conditions and symptoms. Stem cell reconstructive therapy so considered regenerative medicine, and it promotes the repair of patients by using stem cells. This stem cell therapy showing promising results.


due to the adoption of Stem cell reconstructive surgery in a variety of conditions. Stem cell reconstructive surgery is used to treat cardiovascular diseases in which the disease can cause scar tissue. And it is also used to heal wounds and incisions. As Stem cell reconstructive surgery can enhance the growth of new skin tissue, and enhance collagen production, substitute the scar tissue, so it is widely used to treat many medical conditions. Stem cell reconstructive therapy is also used in the treatment of neurodegenerative diseases. Transplanted new adult cells can work in the formation of new brain neurons and cells. A wide range of applications of Stem cell reconstructive will boost the Stem cell reconstructive Industry.


Covid-19 analysis


The covid-19 outbreak was due to the spread of deadly coronavirus, and it is now a global pandemic. Many people are suffering because of the financial crisis and the downfall of the global economy. Businesses around the world are highly affected due to the pandemic. As a result, it has a negative impact on the Stem cell reconstructive market and the allogeneic stem cells market as well.  The cost of stem-cell reconstructive and plastic surgery is very high; as a result, people can’t afford the treatment due to the financial crisis. Many people have lost their jobs and source of income, so they are not ready to invest in such a procedure. Apart from that, hospitals are not more concerned about the spread of coronavirus, and they are fighting against it. All focus has shifted in controlling the spread of the virus; as a result, it is affecting the Stem cell reconstructive industry. Also, the imposition of lockdown by the government in many countries has also affected the Stem cell reconstructive market growth. 


Market segmentation


The Stem cell reconstructive is growing due to the presence of market drivers like that the presence of the market restraints hampering the Stem cell reconstructive industry demand.


Market drivers


The stem cell is a cell that is capable of perpetuating its cell division and has the ability to produce cells with specialized functions. Stem cells are used in the treatment of major diseases such as diabetes, cancer, and others. Stem cells have shown great results for the diseases. According to the data of the international diabetes federation, 420 people were suffering from diabetes across the world. And the increasing patient population has increased the demand for new treatment methods that is a major driver in the Stem cell reconstructive industry. The Advancement of technology and increasing investment in the healthcare sectors by government and other government initiatives are contributing highly to the Stem cell reconstructive market growth.  Stem cell reconstructive also used to treat the dented or injured part of the body due to accidents or other diseases.


Market opportunities


The government is taking many initiatives to provide the best healthcare possible to the patients, and it is generating new opportunities for the Stem cell reconstructive market. Stem cell reconstructive is used to treat various diseases in an effective way; that is why the hospitals are adopting these advanced treatments to provide effective healthcare to the patients. Stem cell reconstructive is also used in cosmetic surgeries and plastic surgeries as a result of an accident or injury. Stem cell reconstructive therapy offers effective solutions in plastic surgery. And with the increasing need for plastic surgery bringing more opportunities to the Stem cell reconstructive industry. Apart from that, with changing lifestyles and increasing per capita income, people can invest in cosmetic surgery or Stem cell reconstructive surgery. So, Economic development is also generating Stem cell reconstructive industry opportunities.


Market restraints


Stem cell reconstructive is very costly, and the high expenditure has become one of the major restraints of the Stem cell reconstructive market. Apart from that, new government regulations on the approval of Stem cell reconstructive has also become a restraint in the Stem cell reconstructive market.


Market challenges


The Stem cell reconstructive market faces challenges just like other markets. There are many underdeveloped areas where advanced treatment procedure is not available due to lack of Technological Advancement, and it has become a major challenge for the Stem cell reconstructive market. The market key players and the drivers are likely to overcome these challenges and boost the Stem cell reconstructive market Demand in the forecast period.


Market segmentation


The Stem cell reconstructive market is divided on the basis of sources, cell types, applications, end-users, and regions.



  • By sources


On the basis of sources, the market is further divided into allogeneic, syngeneic, autologous, and others.  Autologous is further divided into adipose tissue, bone marrow, and blood.



  • By cell types


On the basis of cell types, the market is divided into embryonic stem cells and adult stem cells.



  • By application


Stem cell reconstructive market application segment divided on the basis of cancer, severe burn, diabetes, traumatic skin defect, and others.



  • By end-user


On the basis of end-user, the market is divided into hospitals, research institutes, and others.



  • By regions


The region segment of the market includes North America, Europe, Asia Pacific, and the rest of the world.


Regional analysis


The major regions in the Stem cell reconstructive market are North America, Europe, Asia Pacific, and the rest of the world. The North American region holds the highest Stem cell reconstructive market share due to the advanced healthcare sector and a large patient pool. A large number of patients in Canada and the US also a high percentage of cancer & diabetes patients driving the Stem cell reconstructive industry in this region. Also, strong economy is another driver in the growth of the Stem cell reconstructive industry in this region.


Europe holds the second highest Stem cell reconstructive industry share due to the high investment in stem cell research. Further, the identification of new cells will boost the Stem cell reconstructive market. No regulations and the high amount of funding is one of the major drivers behind the Stem cell reconstructive industry growth in this region.


The Asia Pacific is still developing with the increasing demand for Stem cell reconstructive surgeries in the countries like Japan and Australia, and also increasing the number of cell suppliers in China, India, and Australia will boost the market in the coming years. Government and private partnership agreements and increasing cell-based research will propel the Stem cell reconstructive industry in the forecast period.


Competitive landscape


The major key players in the Stem cell reconstructive market are:



  • Cynata (Australia),

  • Celyad (Belgium),

  • Capricor Therapeutics (Canada),

  • Micronit Microfluidics (Netherlands),

  • TAKARA BIO INC.(Japan),

  • Tigenix (Belgium) Baxter (US),

  • Cytori Therapeutics Inc. (US),

  • Eleveflow (France),

  • Mesoblast Ltd. (Australia),

  • NuVasive Inc. (US),

  • Osiris Therapeutics, Inc. (US)

  • Pfizer Inc. (US)


Recent developments


San Diego Academy of Regenerative Therapies Features Update on Clinical Trial Treating Post COVID Patients with the help of cells from fat tissue.



Report Scope:

Report Attribute/Metric Details
  Market Size   2030: USD 4,673.3 Million
  CAGR   20.6% (2022-2030)
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Sources, Cell Types, Application, End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Baxter (US), Cytori Therapeutics Inc. (U.S), Eleveflow (France), Mesoblast Ltd. (Australia), NuVasive Inc. (US), Osiris Therapeutics, Inc. (US), Micronit Microfluidics (Netherlands), TAKARA BIO INC.(Japan), Tigenix (Belgium), Cynata (Australia), Celyad (Belgium), Capricor Therapeutics (Canada), Astellas Pharma US, Inc. (US), Pfizer Inc. (US), StemCells Inc (US), STEMCELL Technologies Inc. (US), Caladrius (US).
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers

  • Increasing number of geriatric population
  • Rising number of patients suffering from chronic diseases
  • Continuous development in the technology.


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    Stem cell reconstructive surgery uses stem cells to replace injured body parts. As stem cells can take on the form of any human cell, this technique has gained popularity in the medical sector.

    The Stem Cell Reconstructive Market is expected to exhibit a strong 20.6% CAGR over the forecast period from 2022 to 2030.

    Growing investigation into the remedial capabilities of stem cells is the major driver for the Global Stem Cell Reconstructive Market.

    The Americas hold a dominant 45% share in the global market.

    Leading players in the Stem Cell Reconstructive Market include Baxter, Eleveflow, and Mesoblast Ltd., among others.